Pharmaceutical Pre Formulation

77
PHARMACEUTICAL PREFORMULATION R & D (M.Pharm Pharmaceutics)

Transcript of Pharmaceutical Pre Formulation

Page 1: Pharmaceutical Pre Formulation

PHARMACEUTICAL PREFORMULATION

R & D (M.Pharm Pharmaceutics)

Page 2: Pharmaceutical Pre Formulation

What is Preformulation ?

It can be defined as an investigation of physical and chemical properties of a drug substance - alone and when combined with excipients.

Preformulation is the first step in the rational development of dosage forms of a drug substance.

Page 3: Pharmaceutical Pre Formulation

The overall objective of preformulation testing is to generate information useful to the formulator in developing stable and bioavailable dosage forms which can be mass-produced.

Page 4: Pharmaceutical Pre Formulation

Properties associated with drug

Bulk properties (Physical Properties)

Physicochemical properties Stability considerations Biopharmaceutical

considerations

Page 5: Pharmaceutical Pre Formulation

Bulk / Physical Properties

Page 6: Pharmaceutical Pre Formulation

Bulk / Physical Properties

Organoleptic Particle size, shape, and surface

area Crystallinity and polymorphism Water adsorption /

Hygroscopicity.

Page 7: Pharmaceutical Pre Formulation

Bulk / Physical Properties

Bulk density Adhesion Powder flow Compressibility

Page 8: Pharmaceutical Pre Formulation

Colour: Colour can be useful when describing different batches of

drug it can sometimes be used as an indicator of solvent presence or, more importantly, of degradation. In addition, subtle differences in colour may be due to variations in the particle size distribution.

Usually colour is subjective and is based on individual perception; however, more quantitative measurements can be obtained by using, e.g.,tristimulus colorimetry

The shelf life of the formulations could be specified using the Commission Internationale de’Ecalarage (CIE) system for colour.

Organoleptic Properties

Page 9: Pharmaceutical Pre Formulation

Odour: No strong odours should be present. Any deviation from the substance’s

characteristic odour is to be considered and checked for degradations in the substance.

Page 10: Pharmaceutical Pre Formulation

Taste: Unpalatable decreasing the solubility

(in case of DPI’s) supressed by coating

flavours excipients

Page 11: Pharmaceutical Pre Formulation

Particle size, shape, and surface area

Particle size: General Techniques For Determining

Particle Size Microscopy Sieving (Quantitative particle size distribution

analysis) Electronic means

Blockage of electrical conductivity path (coulter counter)

Light scattering Laser scattering

Page 12: Pharmaceutical Pre Formulation

Common Techniques for Measuring Fine Particles of Various Sizes

Technique Particle size (mm)

Microscopic 1 - 100Sieve > 50Sedimentation > 1Elutriation 1 - 50Centrifugal < 50Permeability > 1Light scattering 0.5 - 50

Page 13: Pharmaceutical Pre Formulation

Determination of Surface Area

Brunauer-Emmett-Teller (BET) method

Dynamic method of gas adsorption

Page 14: Pharmaceutical Pre Formulation

Some facts of surface area At relatively large diameters, the specific surface

area is insensitive to an increase in diameter At very small diameters the surface area is

comparatively very sensitive. Relatively high surface area most often reflects a

relatively small particle size, except porous or strongly agglomerated mass

Small particles (thus of high surface area) agglomerate more readily, and often to render the inner pores and surfaces inaccessible to dissolution medium

Page 15: Pharmaceutical Pre Formulation

Particle shape Particle shape is of consideration in the

flow properties of the drug. The particle shape (crystalline structure)

can be changed to our convenience and requirements by controlled recrystallization.

Page 16: Pharmaceutical Pre Formulation

Crystallinity and polymorphism Polymorphism is a solid crystalline phase

of a given compound resulting from the possibility of at least two different arrangements of that compound in the solid state.

Page 17: Pharmaceutical Pre Formulation

Polymorphism study is conducted to:

Manufacture the desired forms consistently

Understand the effects of pharmaceutical manipulations , e.g : granulation, milling and compression

Evaluate and predict the storage conditions on dosage forms e.g : crystal growth in creams, suspensions and MDI’s.

Page 18: Pharmaceutical Pre Formulation

Polymorphism can be screened by: Crystallization from different solvents at

different speeds and temperatures Precipitation Concentration or evaporation Crystallization from the melt Grinding and compression Lyophilization Spray drying

Page 19: Pharmaceutical Pre Formulation

Crystal habit Crystal morphology or habit is important,

since it can influence many properties of the compound. For example, powder flow properties, compaction and stability have all been found to be dependent on crystal morphology.

Page 20: Pharmaceutical Pre Formulation

Examples of crystal habits

Page 21: Pharmaceutical Pre Formulation

Overcoming crystallinity problems If a particular formulation is unstable or

having problem in formulation due to the crystal habit of the substance, then it is recrystallized from different solvents to obtain the required crystal habit.

The effect of impurities on the crystal habit should not be overlooked, as these can act as crystal poisons or promote growth in a particular crystallographic direction

Page 22: Pharmaceutical Pre Formulation

The most accurate way of determining the symmetry of a crystal is to use an optical goniometer to measure the angles between the crystal faces.

Page 23: Pharmaceutical Pre Formulation

Hygroscopicity Many compounds and salts are sensitive to

the presence of water vapour or moisture. When compounds interact with moisture, they retain the water by either bulk or surface adsorption, capillary condensation, chemical reaction.

Deliquescence is where a solid dissolves and saturates a thin film of water on its surface.

Page 24: Pharmaceutical Pre Formulation

Degree of hygroscopicity Slightly hygroscopic: Increase in mass is

less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Page 25: Pharmaceutical Pre Formulation

Very hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

Page 26: Pharmaceutical Pre Formulation

Bulk density The density of a powder sample is

usually referred to as the bulk density, and the volume includes both the particulate volume and the pore volume.

Minimum bulk density is when the volume of the powder is at a maximum, caused by aeration, just prior to complete breakup of the bulk.

Page 27: Pharmaceutical Pre Formulation

Poured bulk density is when the volume is measured after pouring powder into a cylinder, creating a relatively loose structure.

Tapped bulk density is, in theory, the maximum bulk density that can be achieved without deformation of the particles.

Page 28: Pharmaceutical Pre Formulation

Powder flow Good flow properties are a prerequisite for

the successful manufacture of both tablets and powder-filled hard gelatin capsules.

It is a property of all powders to resist the differential movement between particles when subjected to external stresses.

This resistance is due to the cohesive forces between particles.

Page 29: Pharmaceutical Pre Formulation

Three principal types of interparticle force have been identified

forces due to electrostatic charging vander Waals forces forces due to moisture

Page 30: Pharmaceutical Pre Formulation

Measuring Powder Flow Properties Shear Cell Method

Page 31: Pharmaceutical Pre Formulation
Page 32: Pharmaceutical Pre Formulation

Powders with particles below 50 µm will generally exhibit irregular or no flow due to vander Waals forces

Particle shape is also important; for example, the force between a sphere and plane surface is about twice that between two equal sized spheres.

Page 33: Pharmaceutical Pre Formulation

Changes in Bulk Density: The increase in bulk density of a powder is

related to the cohesivity of a powder. Ratios of the poured to tapped bulk densities are expressed in two ways to give indices of flowability.

Page 34: Pharmaceutical Pre Formulation

The Hausner Ratio varies from about 1.2 for a free-flowing powder to 1.6 for cohesive powders.

Page 35: Pharmaceutical Pre Formulation

The Carr Index classifications are

Page 36: Pharmaceutical Pre Formulation

Angle of Repose If powder is poured from a funnel onto a

horizontal surface, it will form a cone. The angle between the sides of the cone and the horizontal is referred to as the angle of repose.

angles less than 30°are usually indicative of good flow, while powders with angles greater than 40°are likely to be problematic.

Page 37: Pharmaceutical Pre Formulation

Physico-chemical properties

Page 38: Pharmaceutical Pre Formulation

Physico-chemical properties Solubility analysis Ionization Partition coefficients Dissolution

Page 39: Pharmaceutical Pre Formulation

Solubility Solubility is the extent of drug that goes

into solution form.

Page 40: Pharmaceutical Pre Formulation

Solubility standards

Page 41: Pharmaceutical Pre Formulation

Many drugs are ionizable organic compounds, and thus there are a number of parameters that will determine the solubility of a compound. These parameters include, e.g., molecular size and substituent groups on the molecule, degree of ionization, ionic strength, salt form, temperature, crystal properties and complexation.

Page 42: Pharmaceutical Pre Formulation

Determination of Solubility

Solvent(fixed volume)

Adding solute in smallincremental amounts

Vigorously shaking

Undissolvedsolute particles ?

Examinevisually

YesNo

Total amountadded upEstimated solubility

Semiquantitative determination:

Page 43: Pharmaceutical Pre Formulation

Accurately Quantitative determination:Excess drug powder150 mg/ml (15 %)+ solvent

Ampul/vial(2-5 ml)

Shaking at constant temperature (25 or 37 oC)

2 - 8 oC ?

Membrane filter0.45 mm

Determine the drugconcentration in the

filtrate

Determine the drugconcentration in the

filtrate

Determine the drugconcentration in the

filtrate

Membrane filter0.45 mm

Membrane filter0.45 mm

Sameconcentration ?

The first few ml’s of the filtrates should be discarded due to possible filter adsorption

Solubility

48 hr

72 hr

? hr

Page 44: Pharmaceutical Pre Formulation

Highly insoluble drug administered in small doses may exhibit good absorption

Unstable drug in highly acidic environment of stomach, high solubility and consequent rapid dissolution could result in a decreased bioavailability

The solubility of every new drug must be determined as a function of pH over the physiological pH range of 1 - 8

Page 45: Pharmaceutical Pre Formulation

Problems in Solubility Determination of Poorly Soluble Compounds

Solubilities could be overestimated due to the presence of soluble impurities

Saturation solubility is not reached in a reasonable length of time unless the amount of solid used is greatly in excess of that needed to saturation

Page 46: Pharmaceutical Pre Formulation

Many compounds in solution degrade, thus making an accurate determination of solubility difficult

Difficulty is also encountered in the determination of solubility of metastable forms that transform to more stable forms when exposed to solvents

Page 47: Pharmaceutical Pre Formulation

pH-Solubility Profile

Excess drugpowder

Stir in beakerwith distilled

water

Continuousstirring of

suspension

Addacid/base

MeasurepH of

suspension

SOLUBILITY pH

Filter Stirring

Page 48: Pharmaceutical Pre Formulation

2 4 6 8 10 12 14

5

4

3

2

1

Indomethacin(weak acid)

Chlorpromazine(weak base)

Oxytetracycline(amphoteric)

Lo

g a

qu

eou

s so

lub

ility

(m

mo

l)

pH

Page 49: Pharmaceutical Pre Formulation

Enhancing solubility Salt forms Complexation Using mixed solvents Use more soluble metastable

polymorph Use of complexation (eg. Ribloflavin-

xanthines complex) Use of suitable surfactant

Page 50: Pharmaceutical Pre Formulation

Salt forms

Drugs which are acidic or basic in nature, if needed are converted to a stable salt form.

Page 51: Pharmaceutical Pre Formulation

NSAID’s : alclofenac, diclofenac, fenbufen, ibuprofen, naproxenWeak acid pKa ~ 4, low solubility

Salt forms: sodium, N-(2-hydroxy ethyl) piperazinium arginiumN-methylglucosammonium

Solubilitydiclofenac (free acid) : 0.8 x 10 -5 M (25 oC)diclofenac sodium : 24.5 mg/ml (37 oC)

Page 52: Pharmaceutical Pre Formulation

Quinolones enoxacin, norfloxacin,ciprofloxacin

Salt forms lactate, acetate, gluconate,

galacturonate, aspartate,glutamate, etc.

SolubilityFree base : < 0.1 mg/ml (25 oC)Salt forms : > 100 mg/ml (25 oC)

Page 53: Pharmaceutical Pre Formulation

Dissolution Dissolution is the dynamic process by

which a material is dissolved in a solvent and is characterised by a rate (amount dissolved per time unit)

Page 54: Pharmaceutical Pre Formulation

C, Vc

Xc

D Xg

kd ka ke

Absorption site(gi-tract)

Central compartment(blood circulation)

Dissolution Absorption Elimination

Diagram showing dissolution and absorption of solid dosage form into blood circulation

kd << ka “dissolution rate-limited”

Page 55: Pharmaceutical Pre Formulation

Determination of dissolution Dissolution can be determined by

Rotating disk method (Woods apparatus) Nelson constant surface method

Page 56: Pharmaceutical Pre Formulation

Rotating-disk method (Wood apparatus)

Stirring shaft

Tablet die

Lower punch

Compressed tablet

Rubber gasket

Dissolution medium

Page 57: Pharmaceutical Pre Formulation

RotatingPaddle

Tablet surfaceHardened wax

or paraffin

Dissolutionmedium

Nelson Constant Surface method

Page 58: Pharmaceutical Pre Formulation

Particulate Dissolution Particulate dissolution is used to study

the influence on dissolution of particle size, surface area, and mixing with excipients.

The rate of dissolution normally increased with a decrease in the particle size.

Page 59: Pharmaceutical Pre Formulation

Occasionally, however, an inverse relationship of particle size to dissolution is encountered.

This may be explained on the basis of effective or available, rather than absolute, surface area; and it is caused by incomplete wetting of the powder.

Incorporation of a surfactant in the dissolution medium may provide the expected relationship.

Page 60: Pharmaceutical Pre Formulation

Means of enhancing the slow dissolution:

In absence of more soluble physical or chemical form of the drug -

Particle size reduction (most commonly used). Enhanced surface area by adsorbing the drug on an

inert excipient with a high surface area, i.e., fumed silicon dioxide.

Comelting, coprecipitating, or triturating the drug with some excipients.

Incorporation of suitable surfactant.

Page 61: Pharmaceutical Pre Formulation

Partition Coefficient Like biological membrane in general, the gi

membranes are largely lipoidal in character. The rate and extent of absorption decreased with

the increasing polarity of molecules. Partition coefficient (distribution coefficient): the

ratio in which a solute distributes itself between the two phases of two immiscible liquids that are in contact with each other (mostly n-octanol/water).

Page 62: Pharmaceutical Pre Formulation

Partition coefficient K O/W can be determined by spectrophoteometric methods.

Page 63: Pharmaceutical Pre Formulation

Ionization constant The unionized species are more lipid-soluble and

hence more readily absorbed. The gi absorption of weakly acidic or basic drugs is

related to the fraction of unionized drug in solution. Factors affecting absorption:

- pH at the site of absorption

- Ionization constant

- Lipid solubility of unionized species

Page 64: Pharmaceutical Pre Formulation

Henderson-Hasselbalch equationFor acids:

pH = pKa + log [ionized form]/[unionized

form]For bases:

pH = pKa + log [unionized form]/[ionized form]

Page 65: Pharmaceutical Pre Formulation

Determination of Ionization Constant

Potentiometric pH-Titration pH-Spectrophotometry Method pH-Solubility Analysis

Page 66: Pharmaceutical Pre Formulation

pKa Determinations Many potential candidate drugs are weak acids or

bases, therefore, one of the most important determinations carried out prior to development is the pKa or ionization constant. Strong acids, e.g., HCl, are ionized at all pH values, whereas the ionization of weak acids is dependent on pH. It is useful to know the extent to which the molecule is ionized at a certain pH, since properties such as solubility, stability, drug absorption and activity are affected by this Parameter.

Page 67: Pharmaceutical Pre Formulation

Methods for the determination of pKa

Potentiometric titration UV spectotroscopy Solubility measurements HPLC techniques Capillary zone electrophoresis Foaming activity

Page 68: Pharmaceutical Pre Formulation

Stability considerations

Page 69: Pharmaceutical Pre Formulation

Stability Solid state

Relative Humidity Compatibility

Page 70: Pharmaceutical Pre Formulation

Solution pH Buffer Solvent Temperature

Page 71: Pharmaceutical Pre Formulation

Compatibility with excipients All the drug substances are checked for

their compatibility with the excipients, and their stability in the dosage form.

Page 72: Pharmaceutical Pre Formulation

Biopharmaceutical considerations

Page 73: Pharmaceutical Pre Formulation

Absorption Route Rate Extent Mechanism Absorption windows Food effects

Page 74: Pharmaceutical Pre Formulation

Metabolism First pass metabolism Enzyme induction Metabolism in GIT

Page 75: Pharmaceutical Pre Formulation

Duration of action Dosing Controlled release

Page 76: Pharmaceutical Pre Formulation

REFERENCES: Modern Pharmaceutics – Gilbert.S.Banker Theory and Practice of Industrial Pharmacy – Leon Lachman Solid Dosage Forms Vol 1 - Lachman & Lieberman Liquid Dosage Forms (Parenterals)Vol 1 - Lachman &

Lieberman Preformulation in Solid Dosage Form Development - Moji

Christianah Adeyeye, Harry G. Brittain. Stability of Drugs and Dosage Forms - Sumie Yoshioka Pharmaceutical Preformulation And Formulation A Practical

Guide From Candidate Drug Selection To Commercial Dosage Form – Mark Gibson.

Page 77: Pharmaceutical Pre Formulation

THANK YOU